IDYA
HEALTHCAREIdeaya Biosciences Inc
AI Insight
What's Moving IDYA Today?
No stock-specific AI insight has been generated for IDYA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$20.50$39.28
$36.93
Fundamentals
Market Cap$3.4B
P/E Ratio—
EPS$-1.57
Dividend Yield—
Dividend / Share—
ROE-14.3%
Profit Margin-62.2%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding96.3M
IDYA News
27 articles- IDEAYA Biosciences (IDYA) Is Up 13.2% After New MTAP Trial And Roche Collaboration - Has The Bull Case Changed?Simply Wall Street·Jun 23, 2026
- IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of DirectorsYahoo Finance·Jun 17, 2026
- IDEAYA Biosciences (IDYA) Stock Could Be 81.5% Below Fair Value After Trial MilestoneSimply Wall Street·Jun 17, 2026
- IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung CancersYahoo Finance·Jun 15, 2026
- IDEAYA Biosciences closes $345M public offeringInvesting.com·Jun 11, 2026
- Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy StudyYahoo Finance UK·Jun 11, 2026
- IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesYahoo Finance·Jun 10, 2026
- Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial ResultsBarchart·Jun 9, 2026
- Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Inflation DataYahoo Finance·Jun 9, 2026
- IDEAYA sets $27 price in $300M stock and warrant sale to investorsStock Titan·Jun 9, 2026
- IDEAYA Biosciences prices $300 million stock offeringInvesting.com UK·Jun 9, 2026
- IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Jun 9, 2026
- IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Jun 8, 2026
- What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For ShareholdersYahoo Finance·Jun 6, 2026
- IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic CancerYahoo Finance·Jun 3, 2026
- IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCOYahoo Finance·Jun 1, 2026
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 29, 2026
- IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology SummitMarketbeat·May 26, 2026
- IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 26, 2026
- IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA FilingMarketbeat·May 25, 2026
- IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial DataMarketbeat·May 18, 2026
- Janus Henderson holds 7.27M IDEAYA shares (NASDAQ: IDYA)Stock Titan·May 15, 2026
- Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time ReviewYahoo Finance·May 7, 2026
- IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 5, 2026
- Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsBenzinga·Apr 13, 2026
All 27 articles loaded
Price Data
Open$35.47
Previous Close$34.91
Day High$37.18
Day Low$35.11
52 Week High$39.28
52 Week Low$20.50
52-Week Range
$20.50$39.28
$36.93
Fundamentals
Market Cap$3.4B
P/E Ratio—
EPS$-1.57
Dividend Yield—
Dividend / Share—
ROE-14.3%
Profit Margin-62.2%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding96.3M
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—